Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies

Juntaro Matsuzaki, Hidekazu Suzuki, Toshihiro Nishizawa, Kenro Hirata, Hitoshi Tsugawa, Yoshimasa Saito, Sawako Okada, Seiichiro Fukuhara, Toshifumi Hibi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.

Original languageEnglish
Pages (from-to)1643-1645
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number3
DOIs
Publication statusPublished - 2012 Mar 1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies'. Together they form a unique fingerprint.

  • Cite this